Request Expert

Expert was continuously funded 1990-2018 by the NIH (NCI, NIGMS), typically as PI of 2-3 concurrent R01 grants, and is currently funded by the American Lung Association (2020-2022). Expert published more than 130 reports of original research and reviews that have been cited more than 6000 times (h index = 45) and averaging more than 300 citations annually over the past decade. Publications have appeared in top journals including Nature, Nature Structural and Molecular Biology, Molecular Cell, PNAS, Blood, Cancer Research, Molecular and Cellular Biology, Oncogene, Nucleic Acids Research, and Genetics. He served for 8 years as Chair of the Department of Molecular Genetics and Microbiology in the University of New Mexico School of Medicine, a department with 17-18 faculty and a $6M annual budget. He was Director/co-Director of the UNM Cancer Center Cancer Biology program and in this role helped secure both P20 and P30 Cancer Center support grants. Expert led the CSU Department of Environmental and Radiological Health Sciences, with 40-42 faculty, and a $13M annual budget from 2008-2019 and continues to direct his research lab. Expert holds a patent (Site-Directed Mutagenesis of DNA) that was licensed by three biotechnology companies. Expert has more than 30 years of experience in genetic engineering, and more than 25 years of experience in the fields of cancer biology, eukaryotic DNA repair, and cell signaling responses to DNA damage including replication stress responses. He is a leader in the field of chromatin regulation of DNA repair. His most recent NIH grant focused on molecular mechanisms of cell response to chemotherapeutic agents, largely using molecular genetic approaches. He has served on numerous NIH grant review panels and grant review panels for foreign funding agencies. He led studies of the biological effects of heavy ion (carbon) radiation at the Japan National Institute of Radiological Sciences in his role as NIRS Distinguished Foreign Scientist, and led efforts to transfer US patients to Japan for carbon ion radiotherapy, building a consortium involving CSU, the University of Colorado Denver School of Medicine and Cancer Center, Children's Hospital.

He consulted with a law firm in Washington, DC on a biotechnology patent law dispute; with a South Carolina law firm on an oncology malpractice suit; and with a Canadian law firm on a low-dose radiation exposure suit. He has served as Science Advisory Board member, KromaTid, Inc. KromaTid is a start up biotechnology firm that manufactures molecular cytogenetic and custom gene tracking assays to discover, detect and diagnose the widest range of disease causing mutations – including DNA sequence inversions and translocations – in a single test. Based on Directional Genomic Hybridization™ (dGH), KromaTiD assays generate sequence, location and orientation data from single cells, making them ideal for mixed cell population studies. He has served as member of Scientific Advisory Boards for Employer, University of Texas Medical Branch NASA Specialized Center of Research program, Emory University, and Yale University.